Table 1.
Demographics and patient population characteristics versus healthy blood donors
| Controls | RA | Statistics | |
|---|---|---|---|
|
Age |
50.34 ± 1.5 |
53.03 ± 1.5 |
P = 0.214 |
|
Gender (F/M) |
24/32 |
24/8 |
- |
|
DAS28 |
n.a. |
3.07 ± 1.12 |
- |
|
Bone erosion (pos/neg) |
n.a. |
22/10 |
- |
|
Serum ACPA (pos/neg) |
n.a. |
20/12 |
- |
|
Serum RF (pos/neg) |
n.a. |
19/13 |
- |
|
Serum ANA (pos/neg) |
n.a. |
21/11 |
- |
|
ESR (mm/h) |
n.a. |
16.8 ± 13.1 |
- |
|
CRP (mg/L) |
n.d. |
6.9 ± 5.2 |
- |
|
PBMC (cells/μl) |
1,961 ± 81.69 |
1513 ± 75.90 |
P < 0.0001 |
|
PMN (cells/μl) |
3,641 ± 149.7 |
4575 ± 546.0 |
P = 0.021 |
|
Therapy (yes/no) |
n.a. |
31/1 |
- |
|
DMARDs (yes/no) |
n.u. |
27/5 |
- |
| Biologics (yes/no) | n.a. | 30/2 | - |
F, female; M, male; DAS28, disease activity score; n.a., not applicable; pos, positive; neg, negative; ACPA: anti-citrullinated protein antibodies; RF, rheumatoid factor; ANA, antinuclear antibody; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; n.d., not determined; PBMC, peripheral blood mononuclear cell; PMN, polymorphonuclear leukocyte; DMARD, disease-modifying antirheumatic drug; n.u., not used.